| 000 | 01723 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250518055927.0 | ||
| 264 | 0 | _c20200721 | |
| 008 | 202007s 0 0 eng d | ||
| 022 | _a1872-8332 | ||
| 024 | 7 |
_a10.1016/j.lungcan.2019.08.028 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aZhou, Kexun | |
| 245 | 0 | 0 |
_aCost-effectiveness analysis of pembrolizumab monotherapy and chemotherapy in the non-small-cell lung cancer with different PD-L1 tumor proportion scores. _h[electronic resource] |
| 260 |
_bLung cancer (Amsterdam, Netherlands) _c10 2019 |
||
| 300 |
_a98-101 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Humanized _xadministration & dosage |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Immunological _xadministration & dosage |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects |
| 650 | 0 | 4 |
_aB7-H1 Antigen _xantagonists & inhibitors |
| 650 | 0 | 4 | _aBiomarkers, Tumor |
| 650 | 0 | 4 |
_aCarcinoma, Non-Small-Cell Lung _xdrug therapy |
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHealth Care Costs |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLung Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMarkov Chains |
| 650 | 0 | 4 | _aMolecular Targeted Therapy |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 | _aPropensity Score |
| 650 | 0 | 4 | _aQuality of Life |
| 650 | 0 | 4 | _aRandomized Controlled Trials as Topic |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aJiang, Chenlu | |
| 700 | 1 | _aLi, Qiu | |
| 773 | 0 |
_tLung cancer (Amsterdam, Netherlands) _gvol. 136 _gp. 98-101 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.lungcan.2019.08.028 _zAvailable from publisher's website |
| 999 |
_c30068262 _d30068262 |
||